Illimis secures $42 million in Series B funding to advance GAIA-based Alzheimer’s therapies.

Jul 14, 2025•3 days ago

Amount Raised

$42 Million

Round Type

series b

SeoulTherapeuticsBiotechnologyHealth Care

Description

Illimis has successfully raised $42 million in a Series B funding round to advance its efforts in developing therapeutics for Alzheimer’s disease. The funding will support Illimis in furthering research and development of its GAIA-based therapies. This investment marks a significant step for the company as it works toward creating innovative solutions for Alzheimer's disease.

Company Information

Company

Illimis Therapeutics

Location

Seoul, Seoul, South Korea

About

Illimis Therapeutics is a biotechnology company focused on developing therapeutics for CNS and immune diseases using its innovative GAIA platform. The company aims to create next-generation treatment options for neuro-immune diseases, addressing high unmet medical needs. Illimis actively engages in partnerships with global pharmaceutical companies and research institutions to enhance its drug development capabilities. It has secured various funding and collaborations to advance its research and development efforts.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Illimis secures $42 million in Series B funding to advance GAIA-based Alzheimer’s therapies.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information